{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:52Z","timestamp":1790913712845,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/0019-509x.134598","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T08:45:28Z","timestamp":1402994728000},"page":"5","source":"Crossref","is-referenced-by-count":9,"title":["Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis"],"prefix":"10.4103","volume":"51","author":[{"given":"S","family":"Gundeti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NK","family":"Thota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VG","family":"Linga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Coca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RP","family":"Tara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Raghunadharao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.134598-1","first-page":"290","volume-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"key-10.4103\/0019-509X.134598-2","first-page":"1497","volume-title":"A minute chromosome in human granulocytic leukemia","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"key-10.4103\/0019-509X.134598-3","first-page":"824","volume-title":"Induction of chronic myelogenous leukemia in mice by the P210BCR\/ABL gene of the Philadelphia chromosome","author":"Daley","year":"1990","journal-title":"Science"},{"key":"key-10.4103\/0019-509X.134598-4","first-page":"6649","volume-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-ABL and BCR\/ABL","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/0019-509X.134598-5","first-page":"569","volume-title":"Natural history and staging of chronic myelogenous leukemia","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"key-10.4103\/0019-509X.134598-6","first-page":"1451","volume-title":"Chronic myeloid leukemia-advances in biology and new approaches to treatment","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.134598-7","first-page":"1330","volume-title":"Chronic myeloid leukemia","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.134598-8","first-page":"1441","volume-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.134598-9","first-page":"1031","volume-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.134598-10","first-page":"753","volume-title":"Accelerated and blastic phases of chronic myelogenous leukemia","author":"Giles","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"key-10.4103\/0019-509X.134598-11","first-page":"205","volume-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML working party experience after a 7-year follow-up","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"key":"key-10.4103\/0019-509X.134598-12","doi-asserted-by":"crossref","unstructured":"Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, et al. GIMEMA working party on chronic myeloid leukemia. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792-6.","DOI":"10.3324\/haematol.13068"},{"key":"key-10.4103\/0019-509X.134598-13","first-page":"743","volume-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: Long-term follow-up of the STI571 0102 and 0109 trials","author":"Silver","year":"2009","journal-title":"Haematologica"},{"key":"key-10.4103\/0019-509X.134598-14","first-page":"2292","volume-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.134598-15","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. NCI, NIH, 2010. Available from: .\">http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40."},{"key":"key-10.4103\/0019-509X.134598-16","first-page":"457","volume-title":"Nonparametric estimation from incomplete observations","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"key-10.4103\/0019-509X.134598-17","doi-asserted-by":"crossref","unstructured":"Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.","DOI":"10.1038\/bjc.1977.1"},{"key":"key-10.4103\/0019-509X.134598-18","first-page":"187","volume-title":"Regression models and life tables","author":"Cox","year":"1972","journal-title":"JR Stat Soc B"},{"key":"key-10.4103\/0019-509X.134598-19","first-page":"1981","volume-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.134598-20","first-page":"3032","volume-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.134598-21","first-page":"721","volume-title":"The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase","author":"Jiang","year":"2007","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"key-10.4103\/0019-509X.134598-22","first-page":"30","volume-title":"Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0019-509X.134598-23","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3109\/9780849379567","volume-title":"Staging of chronic myeloid leukemia in the imatinib era: An evaluation of the World Health Organization proposal","author":"Cortes","year":"2006","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.134598-24","first-page":"1213","volume-title":"Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia","author":"Sureda","year":"2003","journal-title":"Haematologica"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:20:13Z","timestamp":1786648813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0019-509X.134598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"alternative-id":["134598"],"URL":"https:\/\/doi.org\/10.4103\/0019-509x.134598","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}